VIP (Vasoactive Intestinal Peptide): Research Overview

• VIP is a 28-amino-acid neuropeptide in the glucagon/secretin family.
• It acts in the gut, brain, lungs, immune system, and blood vessels.
• Research links VIP to anti-inflammatory, bronchodilatory, and circadian roles.
• Animal studies suggest it can reduce arthritis-related inflammation and tissue damage.

What VIP is

Vasoactive intestinal peptide, or VIP, is a 28-amino-acid peptide. It belongs to the glucagon/secretin superfamily and signals through class II G protein-coupled receptors. VIP is made in many tissues, including the gut, pancreas, neocortex, suprachiasmatic nuclei of the hypothalamus, and lungs.

The name comes from its strong vascular effects in the gut. VIP can relax smooth muscle, widen blood vessels, and change blood flow. It also has effects on the heart, digestion, immune signaling, and airway tone. In blood, its half-life is short, about two minutes.

In human testing, VIP is also used as a lab marker. For example, ARUP’s plasma test lists a reference interval of 0 to 89.1 pg/mL and notes its use in diagnosing VIP-secreting tumors, also called VIPomas.

How VIP works in the body

Digestive effects

VIP has several actions in the digestive system. It relaxes smooth muscle in the lower esophageal sphincter, stomach, gallbladder, and enteric tract. It also increases secretion of water and electrolytes into the intestine, stimulates pancreatic bicarbonate secretion, and inhibits gastrin-stimulated gastric acid secretion.

One PubMed study comparing VIP and secretin in conscious dogs found that both peptides inhibited pentagastrin-induced acid secretion. VIP had a wider range of inhibition than secretin because it also inhibited the acid response to histamine. The same study noted reduced gastric mucosal blood flow during some tests and a fall in serum gastrin after a peptone meal.

These actions make VIP part of the gut’s balance system for secretion and motility. In plain terms, it helps coordinate how the stomach and intestines move fluids and respond to meals.

Cardiovascular and airway effects

VIP is a vasodilator, which means it helps widen blood vessels. It can lower arterial blood pressure, stimulate contractility in the heart, and produce positive inotropic and chronotropic effects. It also relaxes smooth muscle in the trachea and gallbladder.

In the lungs, VIP is described in the provided material as the primary endogenous bronchodilator and pulmonary vasodilator. The same source says VIP-deficient states are associated with pulmonary arterial hypertension and airway hyperresponsiveness. That makes VIP a peptide of interest in respiratory biology, though these notes should be read as research context, not as proof of a treatment effect in people.

Brain and circadian effects

VIP is also active in the brain. It is produced by neurons in the suprachiasmatic nucleus, which is the body’s main circadian clock. One source states that VIP helps regulate circadian rhythm entrainment and supports normal sleep-wake cycle maintenance.

Another research summary describes VIP as a chronobiotic signal, meaning it helps shape daily timing. The same material links VIP with hypothalamic signaling and POMC processing, which can support downstream MSH production. This places VIP near other timing and regulation pathways rather than in one isolated role.

VIP and the immune system

Much of the research interest around VIP comes from its immune effects. A major review in PMC describes VIP as an endogenous anti-inflammatory neuropeptide with therapeutic potential in several immune disorders. That review says VIP helps maintain immune tolerance in two main ways: it balances pro-inflammatory and anti-inflammatory signals, and it promotes regulatory T cells that suppress autoreactive T-cell effectors.

Another source describes VIP binding to VPAC1 and VPAC2 receptors on T cells, macrophages, and dendritic cells. In that context, VIP suppresses NF-kB activation and lowers IL-6, TNF-alpha, IL-12, and MMP-9, while increasing IL-10 and TGF-beta1 signaling. Those changes fit a broader anti-inflammatory pattern.

The Johns Hopkins Arthritis summary of a 2001 Nature Medicine study gives a clear example. In mice with collagen-induced arthritis, daily or alternate-day intraperitoneal VIP led to delayed onset, lower incidence, and less severe disease than placebo. Histology showed less inflammatory infiltrate, pannus formation, cartilage destruction, and bone erosion. The summary also reports reduced T-cell clonal expansion, lower Th1 cytokines such as interferon-gamma, higher Th2 cytokines such as IL-4, reduced collagen-specific IgG antibodies, and suppression of inflammatory cytokines like TNF and IL-1.

That same animal work points to a broad shift away from inflammatory and autoimmune activity. It does not prove the same effect in people, but it does explain why VIP remains of interest in rheumatoid arthritis research and related immune models.

What researchers are studying now

Current interest in VIP spans immune regulation, respiratory biology, metabolism, and circadian control. A 2022 paper cited in the supplied material examines VIP and its receptor VPAC2 in type 2 diabetes. Another cited paper, from 2015, looks at regulation of appetite, body composition, and metabolic hormones by VIP. Those titles show that researchers are still mapping VIP beyond inflammation alone.

Some clinic and compounding pages also discuss intranasal VIP as a research or wellness product. One source describes a compounded nasal spray format and lists general dose ranges used in available protocols, such as 0.2 to 0.4 mg daily for inflammatory support and up to 0.4 mg daily for respiratory protocols. Another source says intranasal VIP has been discussed in CIRS contexts. These pages are not the same as high-level clinical proof, but they do show how VIP is being explored in practice settings.

For a peptide platform, the useful point is not that VIP has one fixed use. It is that VIP sits at the intersection of immune signaling, airway tone, digestion, and brain timing. That makes it relevant to several research tracks at once.

Testing and handling

VIP measurement is sensitive to specimen handling. ARUP’s plasma test instructions say the specimen should be collected in a chilled lavender or pink EDTA tube, placed on ice until centrifugation, then frozen at -20 C. The test also lists stability after separation from cells as 4 hours at room temperature, 24 hours refrigerated, and 3 months frozen.

Those handling details matter because VIP is short-lived in blood and may be affected by poor collection or transport. In practical terms, the test is a pre-analytic challenge as much as a lab assay. For any reader looking at VIP testing, that means collection conditions are part of the result.

What VIP can and cannot tell you

VIP is best understood as a biologically active signaling peptide, not a single-purpose molecule. The research shows it can relax smooth muscle, shift secretion in the gut, modulate immune cells, and influence circadian timing. It also appears in disease models where inflammation is a central feature.

At the same time, the provided sources are mostly preclinical, review-based, or lab-test references. The arthritis data are from mice. The digestive effects come from physiology studies. The immune review explains mechanisms, but it does not establish a broad human treatment standard. That is an important limit.

If you are comparing VIP with other research peptides, it may help to read alongside secretin, which appears in the digestive literature as a close comparator. VIP also sits in a different category than simple structural peptides because it acts as both a neurotransmitter-like signal and an immune regulator.

FAQ

What is VIP in simple terms?

VIP is a natural peptide made in the body. It helps control blood vessel tone, smooth muscle relaxation, secretion in the gut, immune signaling, and some circadian functions.

Why do researchers care about VIP?

Researchers care because VIP has a broad anti-inflammatory profile. The supplied sources describe effects on cytokines, T cells, regulatory T cells, airway tone, and arthritis models.

Does VIP affect digestion?

Yes. The research says VIP relaxes gut smooth muscle, increases intestinal water and electrolyte secretion, stimulates pancreatic bicarbonate secretion, and inhibits gastric acid secretion.

What did the arthritis study show?

In mice with collagen-induced arthritis, VIP delayed disease onset, lowered incidence, reduced severity, and improved tissue findings such as less cartilage destruction and bone erosion.

How is VIP tested in the lab?

ARUP’s plasma test uses chilled EDTA collection, ice handling, centrifugation, and freezing. The listed reference interval is 0 to 89.1 pg/mL.